Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STELLAR01: Camrelizumab + dCRT in Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
NCT07530094Phase 2
Key facts
- Status
- Recruiting
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Countries
- 1
- Modality
- Immune Checkpoint Inhibitors
- Drugs
- camrelizumab
- Conditions
- Esophageal Squamous Cell Carcinoma (ESCC)
01
Overview
Phase 2, randomised, open-label trial of camrelizumab in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms). Primary endpoint: Progression-Free Survival at 1 year. Started Dec 2025; status: recruiting.
02
Design
2 arms- Study design
- RandomizedOpen-label
Concurrent + Adjuvant Camrelizumab
Concurrent chemoradiotherapy + camrelizumab followed by camrelizumab maintenance
Adjuvant Camrelizumab
Concurrent chemoradiotherapy followed by camrelizumab maintenance
03
Who it enrols
Patients must have locally advanced unresectable esophageal squamous cell carcinoma, be 18-74 years old, have an ECOG score of 0-2, adequate organ function, and no prior systemic anti-tumor therapy.
04
Endpoints
Primary
Progression-Free Survival
Secondary
Complete Response Rate
Treatment-Related Adverse Events
Overall Survival
Duration of Response
Beyond the preview
Go deeper on NCT07530094.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07530094.